The clinical-stage bet just cashed its first commercial paycheck overseas. What's next?  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

August 14, 2026   |   Read online   Unsubscribe   A Cardiac Biotech With a Data Readout Coming This Month That Could Change the Story A mid-cap cardiac biotech just started collecting real commercial revenue in Europe, and its next trial readout lands before the month is out. Shares are down about 12% over the past month anyway, which is exactly why the setup is worth your time today. Alerts Before Headlines (Sponsored) Stay Ahead with Street Fox Alerts New moves, new momentum, and new opportunities. If you spend too much time waiting for the “right moment” or for influencers to tell you where to put your money, you’re already behind. Sign up for Street Fox stock alerts and start getting market updates by email. On the next page, you can also add your cell number to receive intraday SMS alerts. Don’t wait for the crowd to catch up. Get started now. (By clicking the link above, you agree to receive emails from StreetFox. You can opt out at any time. - Privacy Policy) Cytokinetics, Incorporated August 13 – Pre‑market Ticker: CYTK | Sector: Healthcare (Biotech) | Market Cap: ~$10.21B 30‑Second Take Why now? Cytokinetics is making the jump from a clinical-stage story to a commercial one. Its cardiac myosin inhibitor, aficamten, has launched as MYQORZO in Germany. Management says early interest is running ahead of internal expectations. The next trial readout (ACACIA-HCM) is due before the end of August, with a supplemental FDA filing teed up for Q4. You get an under-followed mid-cap with a defined catalyst calendar, a low beta, and a stock that just gave back 12% while the fundamentals improved. Trade Setup Time frame: Swing to catalyst-driven (2 to 8 weeks) Edge type: Clinical readout + commercial launch inflection The play here is timing. You're not waiting on an earnings print. You're positioning ahead of the aficamten ACACIA-HCM readout later this month, with the supplemental NDA to the FDA queued up for Q4. Layer on a German launch that management says is running ahead of internal targets, and you have two independent shots at moving the stock inside 90 days. Sizing matters. This is a catalyst trade, not a set-and-forget. History Repeating Itself (Sponsored) The Day the Dollar Changed Forever On August 15, 1971, Richard Nixon ended the gold standard—changing the value behind every dollar overnight. Those who acted early positioned themselves ahead of a major shift, while others felt the impact over time. Today, new discussions around monetary policy are drawing renewed attention from investors. The 2026 Gold Guide explains what happened—and why it still matters. Get the free guide now How much does a company's culture factor into your investment decision? Heavily — culture is a leading indicator of long-term performance Somewhat — I consider it but it's hard to quantify so I weight it lightly Minimally — I focus on financial metrics that are actually measurable Not at all — culture analysis is too soft to be reliable Snapshot Table Metric Value Current Stance Price $73.45 Down about 12% over the past month 52-Week Range $34.60 to $88.31 Upper half, roughly 14% under the high Market Cap $10.21B Mid-cap biotech P/E Ratio N/A Pre-profit; commercial ramp just starting Avg Daily Volume 2.1M (3-month average) Liquid enough for swing sizing Beta 0.38 Low correlation to the broad market Chart 1-Month Synopsis: CYTK is down about 12% over the past month, sliding from roughly $86 to $75.64 even as MYQORZO went on sale in Germany. You're getting a cheaper entry into the same catalyst calendar the stock had four weeks ago. Shares still sit in the upper half of the 52-week range and well below the prior high. You're not chasing a top, but you're not bottom-fishing either, so use tighter risk controls than usual. Bull Case  Core thesis: The commercial launch is working. Aficamten, branded MYQORZO overseas, has launched in Germany, and Cytokinetics has said interest in starting treatment is tracking ahead of its own internal expectations. That's the kind of language you want to hear right after a launch. It usually means the sales curve is steeper than the Street modeled. Catalysts: The pipeline is doing real work too. The ACACIA-HCM readout expected later this month is the next catalyst. It's not a bet-the-company trial. But a positive readout broadens the aficamten story from obstructive HCM into non-obstructive HCM, a materially bigger patient population. That's how you get a re-rating. Then there's the label expansion. Management has said a supplemental NDA is going to the FDA in Q4. You get two shots on goal from a single molecule, with a launch already firing. Valuation upside: Mid-cap biotech, low beta (it doesn't tag along with every market swing), and a defined 90-day catalyst calendar. If aficamten reads out clean, your stock re-rates back toward and potentially through the prior high. Bear Case  Launch-stage biotechs are unforgiving. If you're betting on aficamten, know it's up against Bristol-Myers' Camzyos, which has a two-year head start, entrenched cardiology relationships, and a growing prescriber base. Cytokinetics has to win share, not just win patients. The ACACIA-HCM readout is the obvious risk. Late-stage cardiovascular trials in this space have delivered mixed results before, and if the data is muddy- not a clean win and not a clean loss- you could watch the stock drop 20% while the market tries to figure out what to do with the print. Size the position with that in mind. Cash burn is the second issue. Cytokinetics is still spending heavily on the launch and the pipeline. Any weakness in aficamten uptake, or delays in the FDA supplemental filing timeline, and the market will start pricing in dilution risk again. Finally, this is a one-drug story right now. Aficamten does the heavy lifting on the valuation. That works when the launch is on track. It works less well when a competitor lands a formulary win or publishes better real-world data. Quick Checklist  ✅ Thesis still valid after today's close ✅ Volume confirms move above key levels ✅ Catalyst date (ACACIA-HCM readout, late August) double-checked Deep‑Dive Links Latest earnings report Analyst ratings and price targets Short interest data Company profile and investor relations That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned! Best Regards, —Noah Zelvis Everyday Alpha   Everyday Alpha is a publication of Elite Trade Media LLC. Disclosure: Content is for informational and entertainment purposes only and is not investment advice. Do not base investment decisions on this newsletter. Securities mentioned may be owned by our owners or operators, which could affect our objectivity. Consult a licensed financial advisor before making any investment decision. We may receive compensation from advertisers and affiliate links in this email, including for featured third-party offers. Everyday Alpha and its parent company are not registered investment advisors, broker-dealers, or financial planners. Nothing published by Everyday Alpha — including but not limited to newsletters, emails, text messages, social media posts, or website content — constitutes personalized investment advice, a recommendation to buy or sell any security, or an offer or solicitation to purchase or sell any financial instrument. All content is provided strictly for informational and educational purposes. You should not rely on any content published by Everyday Alpha as a substitute for professional financial, legal, or tax advice tailored to your individual circumstances. Always consult a qualified, licensed financial advisor before making any investment decision. Forward-Looking Statements: Content may contain forward-looking statements, including projections, opinions, and expectations regarding future events or financial performance. These statements are based on current information and assumptions at the time of writing and are inherently uncertain. Actual results may differ materially. Everyday Alpha is under no obligation to update or revise any forward-looking statement after publication. No Guarantee of Accuracy: While Everyday Alpha strives for accuracy, we make no representation or warranty — express or implied — regarding the completeness, reliability, or timeliness of any information provided. Errors, omissions, and outdated information may occur. All content is provided "as is" without warranty of any kind. Past Performance: Any reference to past performance of a security, strategy, or index is not indicative of future results. All investments carry risk, including the potential loss of principal. You could lose some or all of your invested capital. Editorial Process Disclosure: Everyday Alpha uses proprietary research tools, including AI, in its editorial process. All content is reviewed and approved by our editorial team before publication. Readers should independently verify any information before making financial decisions. Advertising & Affiliate Disclosure: Everyday Alpha receives compensation from third-party advertisers and may include paid promotions, sponsored content, and affiliate links within its publications. When you click on certain links or sign up for third-party services featured in our content, we may receive a commission or flat fee. This compensation may influence which companies or products are covered and how they are presented, though it does not affect our editorial opinions. Sponsored content is provided by advertisers and does not represent the views of Everyday Alpha. Conflicts of Interest: Contributors, editors, and affiliates of Everyday Alpha may hold positions in securities discussed in our content. These positions may be established or liquidated at any time without notice to readers. Limitation of Liability: Under no circumstances shall Everyday Alpha, its owners, employees, affiliates, or contributors be liable for any direct, indirect, incidental, consequential, or punitive damages arising from your use of or reliance on any content published by Everyday Alpha. By reading, subscribing to, or otherwise engaging with Everyday Alpha content, you acknowledge and agree to the terms above. Update your email preferences or unsubscribe here © 2026 Everyday Alpha 1032 E Brandon Blvd #9644 Brandon, FL 33511, United States